Holen Sie sich die Stockscreener-App
19.48
2.65%
-0.53
Vorhandelsmarkt:
19.01
-0.47
-2.41%
Schlusskurs vom Vortag:
$20.01
Offen:
$20
24-Stunden-Volumen:
1.93M
Relative Volume:
1.69
Marktkapitalisierung:
$876.40M
Einnahmen:
$110.24M
Nettoeinkommen (Verlust:
$-66.44M
KGV:
-12.89
EPS:
-1.5111
Netto-Cashflow:
$-61.12M
1W Leistung:
+7.74%
1M Leistung:
+9.32%
6M Leistung:
+42.19%
1J Leistung:
+27.32%
1-Tages-Spanne:
$18.48
$20.73
1-Wochen-Bereich:
$16.99
$20.73
52-Wochen-Spanne:
$8.80
$32.71
Beta Bionics Inc Stock (BBNX) Company Profile
Firmenname
Beta Bionics Inc
Sektor
Branche
Telefon
949-427-7785
Adresse
11 HUGHES, IRVINE
Compare BBNX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
19.48 | 900.24M | 110.24M | -66.44M | -61.12M | -1.5111 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Eingeleitet | UBS | Buy |
| 2026-01-27 | Eingeleitet | TD Cowen | Hold |
| 2026-01-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-10-01 | Hochstufung | Goldman | Neutral → Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-06-12 | Eingeleitet | Lake Street | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Neutral |
| 2025-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2025-02-24 | Eingeleitet | BofA Securities | Buy |
| 2025-02-24 | Eingeleitet | Lake Street | Buy |
| 2025-02-24 | Eingeleitet | Leerink Partners | Outperform |
| 2025-02-24 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-24 | Eingeleitet | Stifel | Buy |
| 2025-02-20 | Eingeleitet | Ladenburg Thalmann | Neutral |
| 2025-02-20 | Eingeleitet | Robert W. Baird | Neutral |
Alle ansehen
Beta Bionics Inc Aktie (BBNX) Neueste Nachrichten
William Blair initiates Beta Bionics stock rating at Market Perform - Investing.com
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders - GlobeNewswire
Beta Bionics (NASDAQ:BBNX) Trading 4.7% HigherHere's Why - MarketBeat
Beta Bionics (BBNX) Q2 2026 Earnings Call Transcript - AOL.com
Farallon group discloses 595,000-share Beta Bionics (BBNX) stake in 13G/A - Stock Titan
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Raises Target Price to $18 - Moomoo
BofA Securities Adjusts Price Target on Beta Bionics to $18 From $15.50 - marketscreener.com
Beta Bionics, Inc. Stock 12‑Month Price Target Raised to $20.31, Implies 24% Upside - TradingView
BofA Securities Adjusts Beta Bionics Price Target to $18 From $15.50 - marketscreener.com
Beta Bionics (NASDAQ:BBNX) Shares Up 13.7%Should You Buy? - MarketBeat
Beta Bionics, Inc. (BBNX) Stock Analysis: 42% Potential Upside Amidst Innovative Diabetes Solutions - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Lazard Asset Management LLC Buys New Holdings in Beta Bionics, Inc. $BBNX - MarketBeat
Beta Bionics (BBNX) Drops 4.6% to $13.9, Testing Key Support Near $13.21Fair Value Gap - Vinanet
Beta Bionics, Inc. (BBNX) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Beta Bionics, Inc. (NASDAQ:BBNX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Perceptive Advisors LLC Buys 240,000 Shares of Beta Bionics, Inc. $BBNX - MarketBeat
A Quick Look at Today's Ratings for Beta Bionics(BBNX.US), With a Forecast Between $15.5 to $30.4 - Moomoo
Truist Financial Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Piper Sandler Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance - The Manila Times
Earnings call transcript: Beta Bionics misses Q2 2026 EPS as sales rise 38% - Investing.com Canada
Beta Bionics Q2 Results: Sales rise 37.8% YoY to $32M, EPS beats - scanx.trade
UBS Adjusts Price Target on Beta Bionics to $22 From $24, Maintains Buy Rating - marketscreener.com
Beta Bionics, Inc. $BBNX Shares Acquired by Eversept Partners LP - MarketBeat
Beta Bionics Inc (BBNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beta Bionics, Inc. Revenue Breakdown – NASDAQ:BBNX - TradingView
Beta Bionics Inc (BBNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BBNX Q1 2026 Earnings: Narrower Loss Surprises but Shares SlipEarnings Manipulation Risk - Vinanet
Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism - Yahoo Finance
Beta Bionics Inc (BBNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beta Bionics Inc (BBNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Beta Bionics Inc (BBNX) Institutional Confidence - TradingKey
Beta Bionics Inc (BBNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Beta Bionics (BBNX) sees 6.9% stake reported by Divisadero Street group - Stock Titan
BBNX|Beta Bionics Inc|Price:16.097|Chg%:+0.247 - TradingKey
BBNX|Beta Bionics Inc|Price:16.140|Chg%:+0.290 - TradingKey
Beta Bionics Inc (BBNX) Balance Sheet - TradingKey
BBNX Falls 1.74% as Beta Bionics Faces Profit-Taking Near Key SupportCatalyst Driven Stocks - Vinanet
BBNX|Beta Bionics Inc|Price:16.330|Chg%:+0.200 - TradingKey
Beta Bionics (BBNX) Edges Higher as Investors Eye Key Resistance LevelPercent Below MA - dars.gov.et
Beta Bionics Inc. (BBNX) Surges Over 2% as Bullish Momentum BuildsCall Flow Alert - Vinanet
BBNX Maintained by Goldman Sachs -- Price Target Raised to $19.0 - GuruFocus
Goldman Sachs Maintains Beta Bionics(BBNX.US) With Buy Rating, Raises Target Price to $19 - Moomoo
If You Invested $1,000 in Beta Bionics, Inc. (BBNX) - Stock Titan
Beta Bionics Price Target Raised to $22.00/Share From $18.00 by Truist Securities - Moomoo
Truist Raises Price Target on Beta Bionics to $22 From $18, Keeps Buy Rating - Moomoo
Beta Bionics Inc. (BBNX) Q1 2026 Earnings: Narrower‑than‑expected loss masks progress in pivotal pipelineManagement Guidance Update - dars.gov.et
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders - AOL.com
Beta Bionics (BBNX) Edges Higher, Testing Key Resistance After Positive MomentumTRIN Signal - dars.gov.et
Finanzdaten der Beta Bionics Inc-Aktie (BBNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):